Vedolizumab Drug Level (ENTYVIO drug level)

Immunology

Description

Vedolizumab is a therapeutic antibody against alpha-4 beta-7 integrin which is predominantly expressed by T cells with gastrointestinal-homing mechanisms. Vedolizumab binds to this integrin on activated lymphocytes and stops the migration into the intestinal mucosa. Thus, vedolizumab works to suppresses the inflammatory response [1,2].

Patients with moderately to severely active ulcerative colitis and Crohn’s disease, who have had an inadequate response to conventional therapy, or to anti-tumour necrosis factor alpha (TNFa) agents, may go on to be treated with vedolizumab [3].

The clinical efficacy of vedolizumab therapy correlates with the trough level, that is the drug level just before the next application of vedolizumab. Several factors influence the trough level, among them dosage and frequency of vedolizumab infusion, disease activity, individual pharmacokinetics and immune reaction (ie. formation of anti-drug antibodies, ADA) [1,2].

Monitoring vedolizumab drug level can determine if the serum or plasma level is within the optimal therapeutic range. The results help the treating physician to monitor and optimise the therapy [1].

Indications

Monitoring trough Vedolizumab levels

Sample Type

2mL Serum (Gel 5mL Yellow tube) or 2mL Plasma (EDTA). Requests from outside Sheffield: Transport at ambient temperature via Royal Mail or Courier.

Reference Range

Vedolizumab levels should be >3mg/L when taking the medication. Suggested target levels [1]: 37.1mg/L at week 6, 18.4mg/l at week 14 12.7mg/L during maintenance. In the setting of treatment failure: <3mg/L AND positive antibodies - suggest stop Vedolizumab. <12.7mg/L - suggest increase dose.

Turnaround Time

10 days

Testing Frequency

As required

References

Pouillon L, Vermeire S and Bossuyt. Vedolizumab trough level monitroing in inflammatory bowel disease: a state of the art overview. BMC Med. 2019. 17:89 [Ref 1]. Hui S, Sinopoulou V, Gordon M, et al. Vedolizumab for induction and maintenance of remission in Crohn’s disease. Cochrane database of systematic reviews. 2023. Issue 7. Art No, CD013611. [Ref 2]. Ha C and Kornbluth A. Vedolizumab as a treatmen for Crohn’s disease and Ulcerative Colitis. Gastroenterol Hepatol. 2014. 10(12): 793-800. [Ref 3].

See Also

Vedolizumab drug antibodies

Please note: the above information is subject to change and we endeavour to keep this website up to date wherever necessary.

Your contact for this test

You are enquiring about

Vedolizumab Drug Level (ENTYVIO drug level)